Levicept
Manufacturing · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Discovery Park Ramsgate Rd, Sandwich, Ke...Phone Number
+44 7590815398Website
www.levicept.comRevenue
$5.1 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Levicept
Levicept is dedicated to transforming the lives of individuals suffering from chronic pain caused by osteoarthritis. The company focuses on providing effective and well-tolerated analgesic solutions that minimize the risks associated with prolonged opiate use and the side effects of non-steroidal anti-inflammatory drugs (NSAIDs). Their target clients are those enduring chronic pain, seeking safer alternatives for pain management. Levicept is committed to advancing science and conducting clinical trials to support their mission.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Levicept your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Levicept recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Levicept
Click to see if Levicept had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Levicept has new funding data
Product Launch: Get notified when Levicept launches new products
Check if Levicept has recently received funding, and reach out quickly before it becomes old news!
Check out if Levicept is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Levicept, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Levicept
Find 3 more new buyers
Compare Similar Companies to Levicept
Compare insights from companies similar to Levicept, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Levicept
$5.1M
11-50
Private
$16M
2012
N/A
Company Profile Activity
Activity Insights
Levicept is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Levicept is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Levicept.
Levicept financials insights
Gather financial insights about Levicept, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$16M
Levicept Tech Stack
A closer look at the technologies used by Levicept
Levicept News & Media
Levicept to Present Data from Phase II study of LEVI-04 at OARSI 2026 World Congress on Osteoarthritis
SANDWICH, United Kingdom, April 24, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), will today present positive data from its Phase II study of LEVI-04 in patients with pain and disability due to OA of the knee at OARSI 2026 World Congress on Osteoarthritis being held in West Palm Beach, FL 23-26 April.Levicept Announces The Lancet Publication of LEVI-04 Phase II Clinical Trial Results, Showing Significant Reduction in Pain and Symptoms of Osteoarthritis
SANDWICH, United Kingdom, March 30, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announces the publication in The Lancet of positive results of its Phase II study of LEVI-04 in patients with pain and disability due to OA of the knee [LANCET17736]1.Levicept Announces the Appointment of James Sandy as Chief Development Officer
Leadership Team Strengthened to Support Clinical Development of LEVI-04 for Osteoarthritis Leadership Team Strengthened to Support Clinical Development of LEVI-04 for OsteoarthritisLevicept Announces FDA Acceptance of IND Application for LEVI-04, a Potentially Disease-Modifying Treatment for Osteoarthritis
SANDWICH, United Kingdom, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announces the US Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for LEVI-04. This enables the initiation of further clinical development as a potentially disease-modifying treatment for osteoarthritis.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Levicept
Sign Up For FreeTo access detailed company insights
Levicept is dedicated to transforming the lives of individuals suffering from chronic pain caused by osteoarthritis. The company focuses on providing effective and well-tolerated analgesic solutions that minimize the risks associated with prolonged opiate use and the side effects of non-steroidal anti-inflammatory drugs (NSAIDs). Their target clien... Read More
